A novel peptide interferes with Mycobacterium tuberculosis virulence and survival

Sachin Kumar Samuchiwal, Sultan Tousif, Dhiraj Kumar Singh, Arun Kumar, Anamika Ghosh, Kuhulika Bhalla, Prem Prakash, Sushil Kumar, Ashish Chandra Trivedi, Maitree Bhattacharyya, Gobardhan Das, Anand Ranganathan

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Tuberculosis (TB) is a huge global burden, with new and resistant strains emerging at an alarming rate, necessitating an urgent need for a new class of drug candidates. Here, we report that SL3, a novel 33-amino acid peptide, causes debilitating effects on mycobacterial morphology. Treatment with SL3 drastically inhibits the growth of Mycobacterium tuberculosis in vitro as well as in a pre-clinical mouse model for M.tb infection. Microarray analysis of SL3-expressing strain demonstrates wide-scale transcriptional disruption in M.tb. We therefore believe that SL3 and similar peptides may herald a new approach towards discovering new molecules for TB therapy.

Original languageEnglish (US)
Pages (from-to)735-740
Number of pages6
JournalFEBS Open Bio
StatePublished - Nov 2014


  • Antimycobacterial peptides
  • ESAT6
  • Mycobacterium tuberculosis
  • Protein-protein interaction

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'A novel peptide interferes with Mycobacterium tuberculosis virulence and survival'. Together they form a unique fingerprint.

Cite this